ASTCT Pharmacy SIG Journal Club - June 2024

The ASTCT Pharmacy SIG June 2024 Journal Club will air on Wednesday, June 5, 2024 at 2 pm CDT/3 pm EDT. This webinar consists of two, 30-minute journal club presentations, which include 20 minutes for the presentation and 10 minutes for discussion and a Q&A session. In the June Journal Club session, Drs. Krajewski and Sowell will present on two articles related to: (a)efficacy and safety of extended duration letermovir prophylaxis in recipients of hematopoietic stem-cell transplantation and (b)gilteritinib as post-transplant maintenance for acute myeloid leukemia. This session is intended for pharmacists and other members of the health care team who are involved in managing patients undergoing CAR T-cell therapy or hematopoietic stem cell transplant.

Presenters & Articles

Kristyn Krajewski, PharmD

PGY-2 Pharmacy Resident

Hospital at the University of Pennsylvania

Article: Gilteritinib as Post-Transplant Maintenance for Acute Myeloid Leukemia With Internal Tandem Duplication Mutation of FLT3

Hunter Sowell, PharmD

PGY-2 Pharmacy Resident

Vanderbilt University Medical Center

Article: Efficacy and safety of extended duration letermovir prophylaxis in recipients of hematopoietic stem-cell transplantation at risk of cytomegalovirus infection: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Session Learning Objectives:

Upon completion of the activity, participants should be able to:

1. Review impact of FMS-like tyrosine kinase 3 (FLT3) mutation on prognosis and treatment of acute myeloid leukemia (AML).
2. Evaluate efficacy and safety of gilteritinib as post-transplant maintenance for AML with FLT3-internal tandem duplication (ITD) mutation.
3. Identify patients who are most likely to benefit from post-transplant gilteritinib maintenance.
4. Review cytomegalovirus (CMV) infection prophylaxis strategies following hematopoietic stem cell transplant (HSCT).
5. Analyze the efficacy and safety of extended duration letermovir prophylaxis following HSCT in patients at risk of CMV infection.
6. Explore the utility of extended duration letermovir for CMV prophylaxis following HSCT.

ACCREDITED PROVIDER

This activity is jointly provided by The France Foundation and American Society for Transplantation and Cellular Therapy (ASTCT).

In support of improving patient care, this activity has been planned and implemented by The France Foundation and American Society for Transplantation and Cellular Therapy (ASTCT). The France Foundation is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

CREDIT DESIGNATION

Pharmacists

This knowledge-based activity, qualifies for 1.0 contact hours (0.10 CEUs) of continuing pharmacy education credit. Please submit all evaluations and credit requests no later than 30 days after you complete this activity to ensure your credit fulfillment, as CE credit cannot be awarded past 60 days from the activity date. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net).

All other healthcare professionals completing this course will be issued a statement of participation.

The full CE information for this session can be found here.